buyModerate
Baker Bros. Advisors LP bought $25M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 68,618 shares at an average of $364.04, traded Aug 18, 2025, filed Aug 20, 2025.
Conviction score
46Value
$25M
68,618 shares
Holdings after
1,859,091
+36% from before
From 52-week low
+93%
low $202.48, close $391.43
From 52-week high
0%
high $391.43, as of Aug 18, 2025
Score components
- +15RoleDirector
- +25Trade size$25.0M at market
- +6Relative to holdingsHoldings up 36%
- 0Price contextMid range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
MDGLOct 9, 2026 · close 471.75
Since filing Aug 20, 2025: +20.4%SPY +23.7% · excess -3.2%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-110498, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +177 | $353.88 | $63k | 189,014 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +1,923 | $353.88 | $681k | 1,798,184 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +84 | $355.00 | $30k | 189,098 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +916 | $355.00 | $325k | 1,799,100 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +767 | $357.02 | $274k | 189,865 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +8,328 | $357.02 | $3.0M | 1,807,428 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +228 | $358.21 | $82k | 190,093 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +2,472 | $358.21 | $885k | 1,809,900 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +784 | $359.39 | $282k | 190,877 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +8,514 | $359.39 | $3.1M | 1,818,414 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +502 | $361.37 | $181k | 191,379 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +5,443 | $361.37 | $2.0M | 1,823,857 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +515 | $362.39 | $187k | 191,894 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +5,587 | $362.39 | $2.0M | 1,829,444 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +255 | $363.75 | $93k | 192,149 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +2,772 | $363.75 | $1.0M | 1,832,216 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +211 | $366.30 | $77k | 192,360 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +2,289 | $366.30 | $838k | 1,834,505 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +442 | $367.77 | $163k | 192,802 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +4,798 | $367.77 | $1.8M | 1,839,303 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +131 | $368.84 | $48k | 192,933 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +1,419 | $368.84 | $523k | 1,840,722 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +253 | $369.34 | $93k | 193,186 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +2,747 | $369.34 | $1.0M | 1,843,469 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +506 | $371.01 | $188k | 193,692 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +5,494 | $371.01 | $2.0M | 1,848,963 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +933 | $372.16 | $347k | 194,625 | Aug 20, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +10,128 | $372.16 | $3.8M | 1,859,091 | Aug 20, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 45Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $505k 1,183 shares | -11% | |
| 10Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $13M 24,520 shares | -12% | |
| 0Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $154k 280 shares | -0% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $14M 24,800 shares | -12% | |
| 20Weak | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $10M 18,650 shares | -4% | |
| 50Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,400 shares | -2% | |
| 37Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $2.4M 4,173 shares | -29% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $1.1M 1,958 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.